BR112014004239A2 - inibidores de enzima ativadora de nedd8 - Google Patents

inibidores de enzima ativadora de nedd8

Info

Publication number
BR112014004239A2
BR112014004239A2 BR112014004239A BR112014004239A BR112014004239A2 BR 112014004239 A2 BR112014004239 A2 BR 112014004239A2 BR 112014004239 A BR112014004239 A BR 112014004239A BR 112014004239 A BR112014004239 A BR 112014004239A BR 112014004239 A2 BR112014004239 A2 BR 112014004239A2
Authority
BR
Brazil
Prior art keywords
activating enzyme
disclosed
chemical entities
nedd8
inhibitors
Prior art date
Application number
BR112014004239A
Other languages
English (en)
Portuguese (pt)
Inventor
Sue Mccarron Ashley
Stirling Matthew
G Stroud Stephen
B Sells Todd
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BR112014004239A2 publication Critical patent/BR112014004239A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014004239A 2011-08-24 2012-08-23 inibidores de enzima ativadora de nedd8 BR112014004239A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526830P 2011-08-24 2011-08-24
PCT/US2012/052007 WO2013028832A2 (en) 2011-08-24 2012-08-23 Inhibitors of nedd8-activating enzyme

Publications (1)

Publication Number Publication Date
BR112014004239A2 true BR112014004239A2 (pt) 2017-03-21

Family

ID=47747080

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004239A BR112014004239A2 (pt) 2011-08-24 2012-08-23 inibidores de enzima ativadora de nedd8

Country Status (29)

Country Link
US (3) US8809356B2 (enExample)
EP (2) EP3323414A1 (enExample)
JP (1) JP6038150B2 (enExample)
KR (1) KR20140054288A (enExample)
CN (1) CN103889988B (enExample)
AR (1) AR087672A1 (enExample)
AU (1) AU2012298813B2 (enExample)
BR (1) BR112014004239A2 (enExample)
CA (1) CA2846231C (enExample)
CL (1) CL2014000441A1 (enExample)
CO (1) CO6900148A2 (enExample)
CR (1) CR20140128A (enExample)
DO (1) DOP2014000037A (enExample)
EA (1) EA031067B1 (enExample)
EC (1) ECSP14013263A (enExample)
GE (1) GEP201606522B (enExample)
HK (1) HK1199252A1 (enExample)
IL (1) IL231069B (enExample)
MA (1) MA35439B1 (enExample)
MX (1) MX2014002015A (enExample)
MY (1) MY166889A (enExample)
PE (1) PE20141146A1 (enExample)
PH (1) PH12014500419A1 (enExample)
SG (2) SG10201601023UA (enExample)
TN (1) TN2014000080A1 (enExample)
TW (1) TWI577667B (enExample)
UA (1) UA114894C2 (enExample)
UY (1) UY34292A (enExample)
WO (1) WO2013028832A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
HK1199252A1 (en) * 2011-08-24 2015-06-26 Millennium Pharmaceuticals, Inc. Inhibitors of nedd8-activating enzyme
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
US9593121B2 (en) 2012-08-03 2017-03-14 Millennium Pharmaceuticals, Inc. Indole substituted pyrrolopyrimidinyl inhibitors of Uba6
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
CN105492429A (zh) * 2013-07-02 2016-04-13 米伦纽姆医药公司 Sumo活化酶的杂芳基抑制剂
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
PL3164130T3 (pl) 2014-07-01 2020-02-28 Millennium Pharmaceuticals, Inc. Związki heteroarylowe użyteczne jako inhibitory enzymu aktywującego sumo
KR101927375B1 (ko) * 2016-04-20 2018-12-11 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018213258A1 (en) * 2017-05-15 2018-11-22 Millennium Pharmaceuticals, Inc. Treatment of merlin-deficient tumors using nae inhibitors
US12319683B2 (en) 2018-05-08 2025-06-03 Nippon Shinyaku Co., Ltd. Azabenzimidazole compounds and pharmaceutical
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
AU6500696A (en) 1995-07-28 1997-02-26 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
AU2003291024A1 (en) 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
JP2008503591A (ja) 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ, インコーポレイテッド ユビキチンリガーゼ阻害剤
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
JP5231251B2 (ja) * 2006-02-02 2013-07-10 ミレニアム ファーマシューティカルズ, インコーポレイテッド E1活性化酵素の阻害剤
ATE485276T1 (de) * 2006-08-08 2010-11-15 Millennium Pharm Inc Heteroarylverbindungen als hemmer der e1- aktivierenden enzyme
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
RU2562245C2 (ru) * 2009-05-14 2015-09-10 Милленниум Фармасьютикалз, Инк. ГИДРОХЛОРИД (1S,2S,4R)-4-{ 4-[(1S)-2,3-ДИГИДРО-1Н-ИНДЕН-1-ИЛАМИНО]-7Н-ПИРРОЛО [2,3-d]ПИРИМИДИН-7-ИЛ} -2-ГИДРОКСИЦИКЛОПЕНТИЛ)МЕТИЛ СУЛЬФАМАТА
HK1199252A1 (en) * 2011-08-24 2015-06-26 Millennium Pharmaceuticals, Inc. Inhibitors of nedd8-activating enzyme
EP2773360B1 (en) * 2011-11-03 2018-02-28 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and hypomethylating agent

Also Published As

Publication number Publication date
US20180290983A1 (en) 2018-10-11
JP6038150B2 (ja) 2016-12-07
US9850214B2 (en) 2017-12-26
MX2014002015A (es) 2014-03-27
GEP201606522B (en) 2016-08-10
MA35439B1 (fr) 2014-09-01
SG10201601023UA (en) 2016-03-30
UY34292A (es) 2013-04-05
CL2014000441A1 (es) 2014-09-26
EA201400249A1 (ru) 2014-05-30
CR20140128A (es) 2014-05-15
KR20140054288A (ko) 2014-05-08
ECSP14013263A (es) 2014-04-30
TN2014000080A1 (en) 2015-07-01
WO2013028832A2 (en) 2013-02-28
CA2846231A1 (en) 2013-02-28
IL231069A0 (en) 2014-03-31
DOP2014000037A (es) 2014-04-15
CA2846231C (en) 2017-06-20
JP2014524476A (ja) 2014-09-22
CN103889988B (zh) 2018-05-04
US20150011572A1 (en) 2015-01-08
HK1199252A1 (en) 2015-06-26
EA031067B1 (ru) 2018-11-30
MY166889A (en) 2018-07-24
CO6900148A2 (es) 2014-03-20
SG11201400102WA (en) 2014-03-28
PE20141146A1 (es) 2014-09-21
TWI577667B (zh) 2017-04-11
EP2748168A2 (en) 2014-07-02
PH12014500419A1 (en) 2020-06-22
CN103889988A (zh) 2014-06-25
AR087672A1 (es) 2014-04-09
US20130150388A1 (en) 2013-06-13
IL231069B (en) 2018-02-28
US8809356B2 (en) 2014-08-19
AU2012298813B2 (en) 2016-07-28
AU2012298813A1 (en) 2013-05-02
EP3323414A1 (en) 2018-05-23
UA114894C2 (uk) 2017-08-28
WO2013028832A3 (en) 2013-05-02
EP2748168A4 (en) 2015-04-22
NZ622220A (en) 2016-04-29
TW201313689A (zh) 2013-04-01

Similar Documents

Publication Publication Date Title
BR112014004239A2 (pt) inibidores de enzima ativadora de nedd8
BR112014026703A2 (pt) inibidores de dna-pk
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EA201490300A1 (ru) 4-имидазопиридазин-1-ил-бензамиды и 4-имидазотриазин-1-ил-бензамиды в качестве btk-ингибиторов
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
BR112014002675A2 (pt) "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
CY1119056T1 (el) Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
BR112012020693A2 (pt) derivados de ciclobutano e metilciclobutano como inibidores de janus quinase
BR112014007622A2 (pt) inibidores de flt3 cinase macrocíclicos
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
BR112015009942A2 (pt) derivados de tiofeno fundidos tricíclicos como inibidores de jak
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
BR112015021888A2 (pt) inibidores de dna-ik
MX2021013118A (es) Compuestos polifluorados que actuan como inhibidores de la tirosina cinasa de bruton.
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
BR112014011351A2 (pt) inibidores de acc e usos dos mesmos
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
BR112015011456A2 (pt) compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
ECSP099775A (es) Terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario
BR112014007193A2 (pt) derivados de pirazoloquinolinona, preparação dos mesmos e uso terapêutico dos mesmos
EA201170005A1 (ru) Диаминопиридиновые, пиримидиновые и пиридазиновые модуляторы гистаминового рецептора h
BR112015006524A2 (pt) derivados de quinazolinona como inibidores de parp

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements